HAINS Mycobacterium Tuberculosis Second Line Drug Resistance Profile Test
Comprehensive Detection of Drug-Resistant Tuberculosis
The HAINS Mycobacterium Tuberculosis Second Line Drug Resistance Profile Test represents a breakthrough in tuberculosis diagnostics, offering precise molecular detection of resistance to critical second-line anti-TB medications. This advanced testing methodology utilizes sophisticated PCR and line probe assay technology to identify specific genetic mutations that confer resistance, enabling healthcare providers to make informed treatment decisions for complex TB cases.
What This Test Measures and Detects
This specialized molecular assay specifically targets and identifies genetic mutations associated with resistance to second-line tuberculosis drugs, including:
- Fluoroquinolones (levofloxacin, moxifloxacin)
- Injectable agents (amikacin, kanamycin, capreomycin)
- Genetic markers for extensively drug-resistant (XDR) TB
- Mutations in gyrA and gyrB genes for fluoroquinolone resistance
- rrs gene mutations associated with injectable drug resistance
Who Should Consider This Test
This advanced diagnostic test is recommended for individuals experiencing:
- Persistent TB symptoms despite first-line treatment
- Treatment failure with standard anti-TB regimens
- Known exposure to multidrug-resistant TB cases
- Recurrent tuberculosis infections
- Immune-compromised status with suspected TB
- Previous history of incomplete TB treatment
- Healthcare workers with TB exposure risks
Key Benefits of HAINS Second Line Drug Resistance Testing
- Early Detection: Identifies drug resistance before treatment failure occurs
- Personalized Treatment: Enables targeted second-line therapy selection
- Reduced Transmission: Helps prevent spread of drug-resistant strains
- Improved Outcomes: Increases treatment success rates for complex cases
- Rapid Results: Faster turnaround compared to conventional culture methods
- Cost-Effective: Prevents expensive, ineffective treatment courses
Understanding Your Test Results
Your HAINS Mycobacterium Tuberculosis Second Line Drug Resistance Profile Test results will provide clear information about:
- Sensitive Profile: Indicates susceptibility to second-line drugs, allowing standard treatment continuation
- Resistance Detected: Identifies specific drugs to which the TB strain is resistant
- Mutation Patterns: Reveals genetic mutations driving drug resistance
- Treatment Guidance: Your physician will use these results to design an effective, personalized treatment regimen
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| HAINS Mycobacterium Tuberculosis Second Line Drug Resistance Profile Test | $162 USD | $250 USD |
Nationwide Testing Availability
We have comprehensive testing facilities across the United States, serving major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures accessible, reliable TB drug resistance testing for patients nationwide.
Take Control of Your TB Treatment Today
Don’t let drug-resistant tuberculosis compromise your health. Our HAINS Second Line Drug Resistance Profile Test provides the critical information needed for effective treatment planning. With rapid turnaround times and expert molecular analysis, we deliver the answers you need to fight TB successfully.
Call or WhatsApp us now at +1(267) 388-9828 to schedule your test or speak with our tuberculosis specialists. Early detection of drug resistance can save lives and prevent treatment complications.
Note: Sample collection requires submission of 3 mL (2 mL minimum) sputum, bronchoalveolar lavages, bronchial aspirates, or cultured growth on appropriate media in sterile screw-capped containers. Samples must be shipped refrigerated and should not be frozen. Turnaround time: Samples submitted by 11 AM, reports available Friday. No special preparation required.
